Empagliflozin improves gut microbial disturbances and intestinal barrier integrity in STZ-induced type 2 diabetic mice
- 19 August 2026
- journal article
- Published by Bioscientifica in Journal of Endocrinology
- Vol. 270 (3)
Abstract
Intestinal barrier dysfunction and gut microbiota dysbiosis contribute to the pathogenesis of type 2 diabetes mellitus (T2DM). However, the effects of empagliflozin on the gut microbiota–intestinal barrier axis remain incompletely understood. This study investigated whether empagliflozin improves intestinal barrier integrity and gut microbiota profiles in a streptozotocin (STZ)-induced murine model of T2DM. Male C57BL/6 mice were fed a high-fat diet followed by STZ injection to induce T2DM and then treated with empagliflozin (10 mg/kg/day) for 8 weeks. Intestinal barrier-related proteins were assessed by immunofluorescence and western blotting. Gut microbial profiles were analyzed using 16S rRNA gene sequencing. Short-chain fatty acids (SCFAs), lipopolysaccharide (LPS), and inflammatory cytokines were quantified by GC–MS and ELISA. Empagliflozin treatment significantly reduced fasting blood glucose levels and attenuated weight gain in diabetic mice. Diabetic animals exhibited compromised intestinal barrier structure, accompanied by decreased tight junction protein expression (Claudin-1 and ZO-1) and enhanced TLR4/MyD88/NF-κB signaling, which were substantially alleviated following empagliflozin treatment. Concurrently, elevated inflammatory cytokines (IL-1β, IL-6, and TNF-α) and LPS levels were significantly reduced following empagliflozin treatment. Microbiome analyses revealed treatment-associated reorganization of gut microbial communities, including altered β-diversity patterns, shifts in diabetes-related taxa, and modified microbial interaction networks. In addition, empagliflozin increased fecal concentrations of key SCFAs, particularly butyrate and isohexanoate. Empagliflozin was associated with improved metabolic parameters, enhanced intestinal barrier integrity, reduced inflammation, and alterations in gut microbiota composition and predicted metabolic activity. Modulation of gut homeostasis may contribute to the therapeutic benefits of empagliflozin in T2DM.Keywords
This publication has 38 references indexed in Scilit:
- Empagliflozin alleviates doxorubicin-induced myocardial injury by inhibiting RIP3-dependent TLR4/MyD88/NF-κB signaling pathwayBiochemical Pharmacology, 2025
- Variation in type 2 diabetes prevalence across different populations: the key driversDiabetologia, 2025
- Empagliflozin rescues lifespan and liver senescence in naturally aged miceGeroScience, 2024
- Empagliflozin attenuates intestinal inflammation through suppression of nitric oxide synthesis and myeloperoxidase activity in in vitro and in vivo models of colitisInflammopharmacology, 2023
- ggClusterNet: An R package for microbiome network analysis and modularity‐based multiple network layoutsiMeta, 2022
- Gut microbiome, prebiotics, intestinal permeability and diabetes complicationsBest Practice & Research Clinical Endocrinology & Metabolism, 2021
- The Gut Microbiota in Prediabetes and Diabetes: A Population-Based Cross-Sectional StudyCell Metabolism, 2020
- Role of gut microbiota in type 2 diabetes pathophysiologyEBioMedicine, 2020
- Increased intestinal permeability as a risk factor for type 2 diabetesDiabetes & Metabolism, 2017
- From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial MetabolitesCell, 2016